Trials / Completed
CompletedNCT04319731
A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University of Utah · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the effect of purified (acellular) amniotic fluid as a treatment for SARS CoV-2 (COVID19)-associated respiratory failure. Past use of human amniotic products (i.e., membrane and fluid) is FDA-approved for tissue injury and has been used to reduce inflammation and fibrosis in patients with a variety of medical conditions. The investigators hypothesize that using nebulized and/or intravenous purified (acellular) amniotic fluid will reduce both inflammation in patients hospitalized for in SARS CoV-2 (COVID19)-associated respiratory failure, potentially leading to a decrease in respiratory support.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human Amniotic Fluid | Administration of amniotic fluid in SARS-CoV-2 positive patients |
Timeline
- Start date
- 2020-03-20
- Primary completion
- 2020-06-09
- Completion
- 2020-06-09
- First posted
- 2020-03-24
- Last updated
- 2023-04-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04319731. Inclusion in this directory is not an endorsement.